- €941.31m
- €913.90m
- €19.52m
Europe Research Roundup: Admiral, UCB SA, Victrex
Brief: H.C. Wainwright & Co. Initiates Medincell's Coverage With "Buy"
Brief: Medincell FY Operating Loss At EUR 21 Mln
Brief: Medincell Provides Update On Phase 3 Mdc-Cwm Clinical Trial
Teva Pharm Q1 profit misses estimates, revenue risea (updated)
Teva Pharma rises as schizophrenia drug meets main goal of late-stage study
Teva and Medincell's schizophrenia drug meets main goal of late-stage study (updated)
Teva and Medincell's schizophrenia drug meets main goal of late-stage study
Brief: Euronext Paris Suspends Shares in Medincell At The Request Of The Company
Europe Research Roundup: Dassault Systemes, Husqvarna, Swedbank
Development And Licensing Agreement With Abbvie To Develop Next-Generation Long-Acting Injectable Therapies
Brief: Medincell Appoints Philippe Guy As Chairman Of Supervisory Board
Brief: Medincell Posts H1 Income From Ordinary Activities Of EUR 8.2 Million
Brief: Medincell Announces Departure Of CFO Jaime Arango
Brief: Medincell: Completion Of Patient Enrollment In Phase 3 Study Of F14
Brief: Medincell Has Received Last Tranche Of EUR 10 Million From European Investment Bank Loan
Brief: Medincell FY Net Loss Widens To EUR 29.5 Million
Brief: Medincell: Phase 1 Data Of Mdc-Tjk For Schizophrenia Patients
Brief: MedinCell Launches Global Offering For About EUR 25 Mln